New Horizons in Predictive Drug Metabolism and Pharmacokinetics
Drug metabolism, pharmacokinetics and toxicokinetics as determinants of drug attrition and the safety of xenobiotics are critically important. This book presents a comprehensive treatise on the current issues and challenges facing drug metabolism and pharmacokinetics. Readers will find a thorough exploration of their predictive role in impacting drug discovery and development and in improving the success rate and safety assessment of pharmaceuticals and industrial or occupational chemicals. Chapters not only focus on the current state of art, with distinct examples, but on future needs and approaches likely to improve our prediction of potential human risk.
Discussions of critical properties that are determinants of a compound’s metabolic and pharmacokinetic fate follow introductory chapters. The Drug Discovery process increasingly incorporates pharmacokinetics and drug metabolism screening and focus has shifted towards in silico, computational and systems biology approaches. Core chapters reflect this and the recent interest and need to assess the role of transporters, along with drug metabolizing enzymes, as potential determinants of pharmacokinetic behaviour, toxicity and drug-drug interactions. Lastly, chapters cover the issues and factors involved in translating pharmacokinetics from in silico to in vivo and from animal models to man, and postulate future directions and opportunities.
Leading experts from academia, industry and regulatory bodies across the globe contribute their knowledge to this book, which scientists involved in many aspects of the drug discovery process, as well as regulators and postgraduate students, will find a useful resource.
New Horizons in Predictive Drug Metabolism and Pharmacokinetics, The Royal Society of Chemistry, 2015.
Download citation file:
Digital access
Print format
Table of contents
-
CHAPTER 1: How Physicochemical Properties of Drugs Affect Their Metabolism and Clearancep1-26ByMaria Karlgren;Maria KarlgrenDepartment of Pharmacy, Uppsala UniversityBiomedical Centre P.O. Box 580, Husargatan 3SE-75123 UppsalaSweden[email protected]Search for other works by this author on:Christel A. S. BergströmChristel A. S. BergströmDepartment of Pharmacy, Uppsala UniversityBiomedical Centre P.O. Box 580, Husargatan 3SE-75123 UppsalaSweden[email protected]Search for other works by this author on:
-
CHAPTER 2: Role of Solubility, Permeability and Absorption in Drug Discovery and Developmentp27-52ByIsmael J. HidalgoIsmael J. HidalgoSearch for other works by this author on:
-
CHAPTER 3: Models for Nonspecific Binding and Partitioningp53-65ByKen KorzekwaKen KorzekwaPharmaceutical Sciences, The School of Pharmacy, Temple University3307 N Broad St.PhiladelphiaPA 19140USA[email protected]Search for other works by this author on:
-
CHAPTER 4: Cytochrome P450 Mediated Drug Metabolismp66-78ByLars Olsen;Lars OlsenDepartment of Drug Design and Pharmacology, University of CopenhagenDenmarkSearch for other works by this author on:Flemming Steen Jørgensen;Flemming Steen JørgensenDepartment of Drug Design and Pharmacology, University of CopenhagenDenmarkSearch for other works by this author on:Chris OostenbrinkChris OostenbrinkInstitute of Molecular Modeling and Simulation, University of Natural Resources and Life SciencesAustria[email protected]Search for other works by this author on:
-
CHAPTER 5: Non-Cytochrome P450 Enzymes and Glucuronidationp79-130ByJ. Matthew Hutzler;J. Matthew HutzlerQ2 Solutions, Bioanalytical and ADME Labs5225 Exploration DriveIndianapolisIN 46241USA[email protected]Search for other works by this author on:Michael A. ZientekMichael A. ZientekPfizer Inc., Pharmacokinetics, Dynamics, and Metabolism10646 Science Center Drive CB4San DiegoCA 92121USASearch for other works by this author on:
-
CHAPTER 6: Metabolite Profilingp131-151ByJames M. SchmidtJames M. SchmidtSearch for other works by this author on:
-
CHAPTER 7: Application of Humanised and Other Transgenic Models to Predict Human Responses to Drugsp152-176ByC. Roland Wolf;C. Roland WolfCancer Research UK Molecular Pharmacology Laboratory, Jacqui Wood Cancer Centre, University of Dundee, Ninewells Hospital & Medical SchoolDundeeDD1 9SYUK[email protected]Search for other works by this author on:Yury Kapelyukh;Yury KapelyukhCancer Research UK Molecular Pharmacology Laboratory, Jacqui Wood Cancer Centre, University of Dundee, Ninewells Hospital & Medical SchoolDundeeDD1 9SYUK[email protected]Search for other works by this author on:Nico Scheer;Nico ScheerIndependent ConsultantCologneGermanySearch for other works by this author on:Colin J. HendersonColin J. HendersonCancer Research UK Molecular Pharmacology Laboratory, Jacqui Wood Cancer Centre, University of Dundee, Ninewells Hospital & Medical SchoolDundeeDD1 9SYUK[email protected]Search for other works by this author on:
-
CHAPTER 8: Stem Cells and Drug Metabolismp177-201ByEdward J. Kelly;Edward J. KellyDepartment of Pharmaceutics, University of Washington1959 NE Pacific StreetBox 357610SeattleWA 98105USA[email protected]Search for other works by this author on:Jenna L. VoellingerJenna L. VoellingerDepartment of Pharmaceutics, University of Washington1959 NE Pacific StreetBox 357610SeattleWA 98105USA[email protected]Search for other works by this author on:
-
CHAPTER 9: Chemically Reactive Versus Stable Drug Metabolites: Role in Adverse Drug Reactionsp202-226ByThomas A. BaillieThomas A. BaillieSearch for other works by this author on:
-
CHAPTER 10: Integrating Metabolism and Toxicity Propertiesp227-246ByMatthew SegallMatthew SegallSearch for other works by this author on:
-
CHAPTER 11: Metabolomics-Based Approaches to Determine Drug Metabolite Profilesp247-262ByLisa J. Christopher;Lisa J. ChristopherBristol-Myers Squibb Pharmaceutical Co., Department of BiotransformationPrincetonNJ08648USA[email protected]Search for other works by this author on:Ramaswamy Iyer;Ramaswamy IyerBristol-Myers Squibb Pharmaceutical Co., Department of BiotransformationPrincetonNJ08648USA[email protected]Search for other works by this author on:Jonathan L. Josephs;Jonathan L. JosephsThermo Fisher ScientificBridgewaterNJ08873USASearch for other works by this author on:W. Griffith HumphreysW. Griffith HumphreysBristol-Myers Squibb Pharmaceutical Co., Department of BiotransformationPrincetonNJ08648USA[email protected]Search for other works by this author on:
-
CHAPTER 12: Drug–Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspectivep263-282ByCuyue Tang;Cuyue TangForum Pharmaceuticals Inc.225 2nd AvenueWalthamMAUSASearch for other works by this author on:Thomayant PrueksaritanontThomayant PrueksaritanontSearch for other works by this author on:
-
CHAPTER 13: Drug–Drug Interactions: Computational Approachesp283-308ByGeoffrey T. TuckerGeoffrey T. TuckerUniversity of SheffieldUKSearch for other works by this author on:
-
CHAPTER 14: Induction of Hepatic Cytochrome P450 Enzymes: Importance in Drug Development and Toxicityp309-332ByBrian G. Lake;Brian G. LakeCentre for Toxicology, Faculty of Health and Medical Sciences, University of SurreyGuildfordSurreyGU2 7XHUK[email protected]Search for other works by this author on:Roger J. PriceRoger J. PriceCentre for Toxicology, Faculty of Health and Medical Sciences, University of SurreyGuildfordSurreyGU2 7XHUK[email protected]Search for other works by this author on:
-
CHAPTER 15: Current Status and Implications of Transporters: QSAR Analysis Method to Evaluate Drug–Drug Interactions of Human Bile Salt Export Pump (ABCB11/BSEP) and Prediction of Intrahepatic Cholestasis Riskp333-347ByToshihisa Ishikawa;Toshihisa IshikawaNGO Personalized Medicine & Healthcare4-17-30 Kiriga-okaMidori-kuYokohama 226-0016Japan[email protected]Graduate School of Bioscience and Biotechnology, Tokyo Institute of TechnologyNagatsutaYokohama 226-8501JapanSearch for other works by this author on:Takeaki Fukami;Takeaki FukamiBioTec Co., Ltd2-29-4 YushimaBunkyo-kuTokyo 113-0034JapanSearch for other works by this author on:Makoto Nagakura;Makoto NagakuraBioTec Co., Ltd2-29-4 YushimaBunkyo-kuTokyo 113-0034JapanSearch for other works by this author on:Hiroyuki HiranoHiroyuki HiranoGraduate School of Bioscience and Biotechnology, Tokyo Institute of TechnologyNagatsutaYokohama 226-8501JapanSearch for other works by this author on:
-
CHAPTER 16: Formulation for Optimizing Bioavailabilityp348-358BySuma GopinathanSuma GopinathanSearch for other works by this author on:
-
CHAPTER 17: Systems Pharmacology Modelingp359-390ByHugh A. Barton;Hugh A. BartonWorldwide Research and Development, Pfizer, Inc.Eastern Point Rd, MS8220-4503GrotonCT 06340USA[email protected]Search for other works by this author on:Harvey J. Clewell, III;Harvey J. Clewell, IIIThe Hamner Institutes for Health Sciences6 Davis Drive, Research Triangle ParkNC 27709USASearch for other works by this author on:Miyoung YoonMiyoung YoonThe Hamner Institutes for Health Sciences6 Davis Drive, Research Triangle ParkNC 27709USASearch for other works by this author on:
-
CHAPTER 18: Pharmacokinetic–Pharmacodynamic Modeling in Drug Development with Special Reference to Oncologyp391-413ByMaria Luisa Sardu;Maria Luisa SarduDipartimento di Ingegneria Industriale e dell’Informazione, Universita’ di PaviaVia Ferrata 327100 PaviaItalySearch for other works by this author on:Giuseppe De Nicolao;Giuseppe De NicolaoDipartimento di Ingegneria Industriale e dell’Informazione, Universita’ di PaviaVia Ferrata 327100 PaviaItalySearch for other works by this author on:Italo PoggesiItalo PoggesiQuantitative Sciences/Model-Based Drug Development, Janssen-Cilag SpAVia Michelangelo Buonarroti 2320093 Cologno Monzese (MI)Italy[email protected]Search for other works by this author on:
Spotlight
Advertisement
Advertisement